Coronavirus

Investigators compare infection rates among heathcare workers throughout different coronavirus epidemics, including SARS, COVID-19, and MERS.

The largest US prospective study of patients to date shows most COVID-19 patients in the ICU are older, minorities, have underlying cardiometabolic disease—and are highly likely to require mechanical ventilation.

A daily news update on our COVID-19 coverage.

Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP chats with assistant editor Grant M. Gallagher on the evolving nature of outpatient infectious disease care in light of the COVID-19 pandemic.

Adam Brufsky, MD, discusses the potential of multiple SARS-CoV-2 viral strains.

Researchers and epidemiologists are working tirelessly to understand clusters that shed new insight into transmission dynamics.

Today's trending stories in infectious disease news.

Miriam Isola, PhD, talks to us about the use of phone apps for COVID-19 contact tracing.

The new kit will have association with multiple certified labs for diagnostics, and will come at no profit for the maker company.

In all trial participants to date, the vaccine candidate led to seroconversion with binding antibody levels either at or above levels seen in convalescent sera.

Armand Balboni, MD, PHD, CEO of Appili Therapeutics, discusses work with favipiravir on a new front for the drug — the global search for COVID-19 treatment and prevention therapies.

A risk score that predicts critical illness in patients hospitalized with COVID-19 could help inform allocation of clinical resources.

Patient stratification, demographic representations, and plasma collection could aid the pursuit for an efficacious prophylaxis.

New cases came to the attention of public health officials within Shulan on May 7.

A summary of Contagion's top stories for May 15, 2020.

Elizabeth Leung, PharmD, shares SIDP's educational efforts surrounding COVID-19 treatment.

An antibody candidate from Sorrento has shown complete blockage of infection in early assessments. The company is now pursuing production and regulatory aid.

New research into a combination of antiviral therapies finds it is safe and appears to shorten disease course in patients with early coronavirus.

A new first-of-its-kind global registry aimed at sharing real-time information on hospital care and ICU admissions could expand the scope of SARS-CoV-2 research.

A briefing on the day's top stories.

In an in vitro reconstituted human respiratory epithelium model, the investigational drug inhibited replication of the novel coronavirus.

In the first part of a discussion with the medical oncologist from UPMC Hillman Cancer Center, Brufsky discusses the potential role of hyperglycemia in severity of COVID-19.

The first-of-its-kind, randomized, placebo-controlled, phase 1/2a trial will assess patients hospitalized at Florida and South Dakota institutions.

New findings comparing cases since February to the last half-decade show the rate and severity of the rare inflammatory disease recently spiked in children.

Vaccine candidate mRNA-1273 has been granted Fast Track designation by the US FDA.

A summary of today's top stories.

Paul Sax, MD, discusses remdesivir, scientific literature in the age of COVID-19, and the pandemic's long-lasting effects on the future of health care.

A series of essays consider the privileges and ethics of an immunity-based "passport" to proceed with fewer restrictions in the age of COVID-19.

Treating severe COVID-19 patients with lopinavir-ritonavir did not have any significant effect compared to standard-care control patients.

A quick summary of the day's infectious disease headlines.